Clinical Trials Browser

Cytokine Release Syndrome × 1 year × Clear all

NCT04975555 2026-06-03

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

Phase 2 Completed

24 enrolled 8 charts

LymphoidOther hematologic neoplasmPlasma cell

Cytokine Release Syndrome, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07499128 2026-06-01

Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event

Phase NA Enrolling by invitation

LymphoidOther hematologic neoplasmPlasma cell

Cytokine Release Syndrome, Lymphoma, Multiple Myeloma, Neoplasms, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07609940 2026-05-27

POPLIN

Phase 4 Not yet recruiting

Cytokine Release Syndrome, Multiple Myeloma

NCT06806033 2026-05-26

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Phase 2 Recruiting

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06377059 2026-05-15

Early Detection of Complications During Immunotherapy for Haematological Malignancy

Phase NA Recruiting

Other hematologic neoplasm

Cytokine Release Syndrome, Hematologic Neoplasms

NCT06421675 2026-04-27

EMBRACE

Phase 2 Recruiting

Cytokine Release Syndrome, Multiple Myeloma, Recurrence

NCT05972135 2026-04-22

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Phase 2 Recruiting

Cytokine Release Syndrome, Multiple Myeloma

NCT07502118 2026-03-30

NexCAR19

Phase 2/3 Recruiting

Cytokine Release Syndrome, Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT07390071 2026-02-05

Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy

Phase NA Recruiting

LymphoidPlasma cell

Cytokine Release Syndrome, Lymphoma, Neoplasms, Plasma Cell

NCT07166549 2025-12-24

BaseCAR-01

Phase 1 Not yet recruiting

LymphoidOther hematologic neoplasm

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, B-Cell, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03696784 2025-12-08

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

Phase 1 Active not recruiting

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, B-Cell, Neurotoxicity Syndromes

NCT04150913 2025-11-25

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

Phase 2 Completed

15 enrolled 17 charts

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Neurotoxicity Syndromes

NCT03016377 2025-10-27

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

Phase 1/2 Active not recruiting

LymphoidOther hematologic neoplasm

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07106671 2025-08-06

A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma

Phase 2 Recruiting

Cytokine Release Syndrome, Neoplasms, Plasma Cell

NCT06703216 2025-06-15

PACER

Phase 1/2 Not yet recruiting

Cytokine Release Syndrome, Burkitt Lymphoma